Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABOS with free AI briefings, catalyst countdowns, and dilution alerts.

ABOS · Acumen Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$78.6M Cash on Hand
10.5mo Cash Runway
Follow ABOS by email Get an email when ABOS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABOS, unsubscribe in one click. Privacy

📣 What ABOS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sabirnetug Alzheimer Disease Phase 2 · NCT06335173 Active not recruiting
ACU193 Alzheimer Disease Phase 1 · NCT04931459 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABOS holds $78.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $22.4M/quarter from operations, an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABOS files for a raise →

👥 Who Owns ABOS

Insiders 4.4% Other 5%+ holders 5% Institutions (132 holders) 67.8% Public and other holders 22.8%
HolderTypeShares% of sharesAs of
James B. Murray Jr. 5%+ holder (13G) 3,611,360 4.99% 2025-04-04
Daniel Joseph OConnell
Chief Executive Officer, Director · +450,000 options
Insider 881,275 1.22% 2026-01-21
RA CAPITAL MANAGEMENT, L.P.
Director, 10% owner · +72,750 options
Insider 588,850 0.81% 2026-06-03
Matt Zuga
CFO & Chief Business Officer · +148,700 options
Insider 304,924 0.42% 2026-01-21
Eric Siemers
Chief Medical Officer · +148,700 options
Insider 255,371 0.35% 2026-01-21
James J. Doherty
President and CDO · +250,300 options
Insider 220,900 0.31% 2026-01-16
John A III Stalfort
Director · +53,250 options
Insider 220,624 0.31% 2026-06-03
Russell Barton
Chief Operating Officer · +126,900 options
Insider 205,092 0.28% 2026-01-21
Derek M Meisner
Chief Legal Officer & Corp Sec · +219,748 options
Insider 173,999 0.24% 2026-03-06
Amy Schacterle
Chief Regulatory Officer · +126,900 options
Insider 92,303 0.13% 2026-01-16
Kimberlee C Drapkin
Director · +53,250 options
Insider 48,300 0.07% 2026-06-03
Laura Stoppel
Director · +53,250 options
Insider 48,300 0.07% 2026-06-03

Share count 72,327,320 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABOS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABOS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.